0001127602-22-024930.txt : 20221103
0001127602-22-024930.hdr.sgml : 20221103
20221103213831
ACCESSION NUMBER: 0001127602-22-024930
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221102
FILED AS OF DATE: 20221103
DATE AS OF CHANGE: 20221103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: REESE DAVID M
CENTRAL INDEX KEY: 0001748434
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37702
FILM NUMBER: 221359957
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 953540776
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER COMPANY:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-11-02
0000318154
AMGEN INC
AMGN
0001748434
REESE DAVID M
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
1
EVP, Research and Development
Common Stock
2022-11-02
4
F
0
2440
272.06
D
48136
D
2,440 shares issuable upon the vesting of Restricted Stock Units (RSUs) and related Dividend Equivalents (DEs) on 11/2/2022 were withheld by the Company to cover related tax withholding obligations.
These shares include the following RSUs granted under the Company's equity plans: 1,534 RSUs which will vest on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 611 DEs granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
/s/ David M. Reese
2022-11-03